Lineage Cell Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Lineage Cell Therapeutics, Inc.‘s stocks are currently a part of 68 hedge funds’ portfolios, which represents 29.44% of the total amount of its stocks outstanding. This makes up a total of 49.97M shares of Lineage Cell Therapeutics, Inc.. Compared to the previous quarter, the number fell by -23.27% or -15.15M shares fewer. As for the holding position changes, 16.18% (11) of current hedge fund investors increased the number of shares held, 26.47% (18) of current holders sold a part of the shares held, and 10.29% (7) closed the holdings completely. 12 hedge funds are new holders of Lineage Cell Therapeutics, Inc. stock in Q1 2023, it is 17.65% of total holders.
Hedge funds holding Lineage Cell Therapeutics (Q2 2019 – Q1 2023)
| Q2 2019 | 1 |
|---|---|
| Q3 2019 | 81 |
| Q4 2019 | 87 |
| Q1 2020 | 81 |
| Q2 2020 | 80 |
| Q3 2020 | 65 |
| Q4 2020 | 75 |
| Q1 2021 | 89 |
| Q2 2021 | 103 |
| Q3 2021 | 108 |
| Q4 2021 | 114 |
| Q1 2022 | 102 |
| Q2 2022 | 86 |
| Q3 2022 | 92 |
| Q4 2022 | 101 |
| Q1 2023 | 68 |
Hedge funds changes in Lineage Cell Therapeutics positions (Q2 2019 – Q1 2023)
| Q2 2019 | 1 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q3 2019 | 81 | 0 | 0 | 1 | -1 |
| Q4 2019 | 16 | 26 | 16 | 10 | 19 |
| Q1 2020 | 6 | 18 | 26 | 11 | 20 |
| Q2 2020 | 18 | 16 | 19 | 18 | 9 |
| Q3 2020 | 2 | 12 | 23 | 17 | 11 |
| Q4 2020 | 18 | 20 | 14 | 9 | 14 |
| Q1 2021 | 24 | 27 | 17 | 8 | 13 |
| Q2 2021 | 33 | 31 | 15 | 20 | 4 |
| Q3 2021 | 15 | 27 | 33 | 9 | 24 |
| Q4 2021 | 20 | 26 | 38 | 14 | 16 |
| Q1 2022 | 11 | 18 | 39 | 22 | 12 |
| Q2 2022 | 14 | 18 | 23 | 29 | 2 |
| Q3 2022 | 15 | 16 | 27 | 8 | 26 |
| Q4 2022 | 25 | 25 | 22 | 14 | 15 |
| Q1 2023 | 12 | 11 | 18 | 7 | 20 |
Hedge funds changes in Lineage Cell Therapeutics stock options (Q2 2019 – Q1 2023)
| Q2 2019 | 0 | 0 |
|---|---|---|
| Q3 2019 | 20,000 | 12,000 |
| Q4 2019 | 0 | 2,000 |
| Q1 2020 | 138,000 | 0 |
| Q2 2020 | 96,000 | 0 |
| Q3 2020 | 67,000 | 1,000 |
| Q4 2020 | 1,437,000 | 69,000 |
| Q1 2021 | 400,000 | 588,000 |
| Q2 2021 | 818,000 | 514,000 |
| Q3 2021 | 1,491,000 | 617,000 |
| Q4 2021 | 1,611,000 | 289,000 |
| Q1 2022 | 389,000 | 117,000 |
| Q2 2022 | 268,000 | 17,000 |
| Q3 2022 | 173,000 | 2,000 |
| Q4 2022 | 82,546 | 3,755 |
| Q1 2023 | 7,392,000 | 3,000,000 |